Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial structure of the organization has undergone a significant shift toward a more equity-heavy capitalization, characterized by a consistent reduction in total liabilities and a corresponding increase in stockholders' equity. Total liabilities as a percentage of the total balance sheet declined from 32.61% in March 2021 to 23.11% by March 2026, indicating a strengthening of the solvency profile and a reduction in financial leverage over the five-year period.
- Liability Composition and Debt Management
- A persistent downward trend is observed in long-term debt, which decreased from 11.13% of total assets and liabilities in March 2021 to 4.86% by March 2026. This steady contraction suggests a strategic deleveraging process. Current liabilities also saw a notable decline, falling from 18.11% to 12.50% over the same period, with a significant step-down occurring between December 2021 and March 2022. Conversely, other noncurrent liabilities exhibited a gradual increase in the latter half of the period, rising from approximately 2.18% in December 2022 to 5.20% by March 2026.
- Equity Growth and Profit Retention
- Stockholders' equity increased from 67.39% in March 2021 to 76.89% in March 2026. This growth was driven primarily by a substantial rise in retained earnings, which climbed from 67.57% to 89.12% of the total balance sheet. This trend indicates strong internal capital generation and the consistent accumulation of profits over time.
- Capital Return Strategy
- The impact of share repurchases is evident in the treasury stock account, which became increasingly negative, moving from -39.02% in March 2021 to -47.50% by March 2026. This suggests that the organization has aggressively returned capital to shareholders through buybacks, even while significantly increasing its retained earnings base.
Overall, the analysis reveals a transition toward a more conservative financial position. The simultaneous reduction in long-term debt and the expansion of retained earnings demonstrate a high degree of financial autonomy and a diminished reliance on external borrowing to fund operations or growth.